Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Insulin Degludec/Liraglutide vs Xultophy in Healthy Chinese Subjects
NCT06449703Phase 1Recruiting
- Sponsor
- Tonghua Dongbao
- Start
- May 2024
- Primary completion
- Jun 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin degludec and liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Tonghua Dongbao. Primary endpoints: Maximum observed plasma insulin degludec concentration, Maximum observed plasma liraglutide concentration and 4 more. Started May 2024; status: recruiting.
02
Drugs
insulin degludecliraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06449703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449703.